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To investigate whether the addition of grip strength and/or self-reported walking pace to 
established CVD risk scores improves their predictive abilities.  
Patients and Methods  
A total of 406,834 participants from UK Biobank, with baseline measurements between March 
13, 2006, and October 1, 2010, without CVD at baseline were included in this study. 
Associations of grip strength and walking pace with CVD outcomes were investigated using 
Cox models adjusting for classical risk factors (as included in established risk scores), and 
predictive utility was determined by changes in C-index and categorical net reclassification 
index (NRI).   
Results 
Over a median of 8.87 years of follow-up (Q1-Q3 8.25-9.47) there were 7,274 composite 
fatal/nonfatal events (based on the ACC/AHA outcome) and 1,955 fatal events (based on 
SCORE). Both grip strength and walking pace were inversely associated with CVD outcomes, 
after adjusting for classical risk factors. Addition of grip strength (change in C-index 
AHA/ACC +0.0017 SCORE +0.0047), usual walking pace (AHA/ACC +0.0031 SCORE 
+0.0130) and both (AHA/ACC +0.0041 SCORE +0.0148) improved the C-index and also 
improved the NRI (grip +0.55%, walking pace +0.53% and combined 1.12%).   
Conclusion 
The current study has shown that the addition of grip strength or usual walking pace to existing 
risk scores results in improved CVD risk prediction, with an additive effect when both are 
added. As both these measures are cheap and easy to administer, these tools could provide an 
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There is strong evidence that better physical capabilities, such as walking pace and grip 
strength, are associated with improved health outcomes. For example, in 2010, a systematic 
review demonstrated that poorer grip strength, walking speed, chair rise time and standing 
balance time were associated with an increase in all-cause mortality risk 1. This has been 
supported in more recent studies where both grip strength and walking pace have been shown 
to be associated with several health outcomes beyond all-cause mortality 2–6.  
 
Indeed, it has been shown, in a study of 800 people, that higher grip strength is associated with 
a lower risk of CVD mortality 7, with similar findings reported in larger studies. For example, 
in a study of 1.1 million men (aged 16-19 years) high muscular strength was associated with 
35% lower CVD mortality, 8 with similar findings in the PURE 9 and Tromsø 10 studies, and 
analyses of the UK Biobank data where a lower risk of incident CVD, including heart failure, 
outcomes was also observed 2,11,12.  Similarly, self-reported walking pace has been shown to 
be strongly associated with CVD mortality. For example, our recent work showing that brisk-
pace walkers have a lower risk of CVD mortality and incidence, compared to slow-pace 
walkers 3. This is further supported by pooled analysis of the Scottish and English Health 
Surveys which found that walking at brisk, relative to slow pace, is associated with a lower risk 
of CVD mortality 13.  
 
Extending these findings, the addition of handgrip strength to an office-based risk score (age, 
sex, diabetes diagnosed, BMI, systolic BP and smoking but without lipids) improved prediction 
of cardiovascular mortality; with a change in the C-index of 0.012 2. Similarly, self-reported 
walking pace has been shown to be a strong predictor of mortality in both men (C-index 0·72 





lifestyle measurements 11 . The effect of adding walking pace to an office-based risk score, to 
our knowledge, remains unexplored. Furthermore, whether grip strength and/or walking pace 
improve established and widely used CVD risk scores, which also include blood lipids, such 
as the AHA/ACC 14 and SCORE 15,16 remains to be established.  
 
The aim of this study, therefore, was to investigate whether the addition of grip strength and/or 




UK Biobank recruited 502,636 participants (aged 37 to 73 years) from 22 assessment centres 
across the UK between April 2007 and December 2010.  A range of baseline biological 
measurements were recorded and touch-screen questionnaires were self-completed, as 
described elsewhere 17,18. UK Biobank received ethical approval from the North West Multi-
Centre Research Ethics Committee (REC reference: 11/NW/03820). All participants gave 
written, informed consent before enrolment in the study, which was conducted in accord with 
the principles of the Declaration of Helsinki.  Date and cause of hospital admission were 
ascertained via record linkage to Health Episode Statistics records for participants in England 
and Wales, and date and cause of death were obtained from death certificates held by the 
National Health Service (NHS) Information Centre for participants from England and Wales 
and the NHS Central Register Scotland for participants from Scotland.  
 
Covariates 
The covariates included in the study models conformed to those used in the published 





continuous covariates) of; age, body mass index (BMI), systolic blood pressure (SBP), diastolic 
blood pressure (DBP), total cholesterol and high density lipoprotein (HDL) cholesterol, and 
categorical variables describing; ethnicity (white, black, South Asian or ‘other’), sex, smoking 
status (never, former or current, or ever/never) and diabetes (present/absent). All models 
excluded participants with CVD (angina, ischaemic stroke, myocardial infarction or transient 
ischaemic attack) reported at baseline.  
 
Systolic and diastolic blood pressure were taken as the first baseline measurement, 
preferentially using an automated measurement (a manual measurement was available in 
33,111 (6.5%) people where an automated measurement was not available). Smoking status 
was categorised into never or former/current smoking. Ethnicity was coded as white, black, 
South Asian, or mixed/other, with white as the referent group. Blood collection sampling 
procedures for the study have been previously described and validated 17. Biochemistry 
measures were performed at a dedicated central laboratory on around 480,000 samples between 
2014 and 2017. These included serum total cholesterol (TC) and high-density lipoprotein 
(HDL) cholesterol (Beckman Coulter AU5400) and plasma glycated haemoglobin (HbA1c, 
Bio-Rad VARIANT II Turbo). Data were adjusted by UK Biobank centrally before release to 
adjust for pre-analytical variables. Further details of these measurements can be found in the 
UK Biobank online showcase and protocol (http://www.ukbiobank.ac.uk).  
 
As described previously 2, the mean grip strength was measured using a Jamar J00105 
hydraulic hand dynamometer and the mean was derived from the right and left hand values 
expressed in absolute units (kg). In the main analyses, these were categorised into sex-specific 





reported walking pace was rated by each participant as ‘slow’, ‘steady/average’ or ‘brisk’, with 
‘steady/average’ used as the referent group. 
 
Outcomes 
The main outcome of interest was that used in the AHA/ACC risk score, namely composite 
fatal or non-fatal incident myocardial infarction, ischaemic heart disease, and haemorrhagic or 
ischaemic stroke (ICD-10 codes I20-25, I60-64 for fatal events and I21,I22, I60, I61, I63 and 
I64 for nonfatal events)14.  We also used the outcome description used in SCORE for fatal CVD 
events which includes ICD-10 codes I10-15, I20-25, I61-73 and I44-5115. A list of the clinical 
entities associated with these codes is included in the supplemental material. 
 
Statistical Analyses 
Continuous variables were expressed as mean (standard deviation, SD). Categorical and binary 
variables were expressed as numbers and percentages. Participants were excluded if they 
reported prevalent or historic CVD at baseline (n=30,687), reported taking cholesterol lowering 
medications (n=58,883) or were missing grip strength (n=3,405) or walking pace (n=2,727) 
measurements.  
 
A risk matrix was developed based on Cox regression models by age and sex strata (40-50, 50-
60, 60+ years for both women and men). Self-reported walking pace and sex-specific quintiles 
of handgrip were mutually adjusted in the models, and were additionally adjusted for ethnicity, 
diabetes, systolic blood pressure, total cholesterol, HDL-cholesterol, and smoking. Cox models 






The effects of the addition of sex-specific average grip strength quintiles, self-reported walking 
pace, or both to the AHA/ACC Cox proportional-hazard model risk score was assessed by the 
change in Harrell’s C-Index for survival data.  To further quantify the additional prediction 
value of handgrip and walking pace, we used a categorical net reclassification index (NRI), 
with 1,000 bootstraps to estimate 95% confidence intervals to investigate the changes in 
predicted risk classification across the 7.5% 10-year risk cut-off used to determine who should 
receive statins in the ACC/AHA model 19.  
 
Interactions between mean grip strength or walking pace and each of the existing AHA/ACC 
risk score covariates were assessed for statistical significance. These analyses were then 
repeated using the CVD outcome and covariates used in the SCORE risk score. The 




Of the original 502,536 participants, 30,687 (6.1%) with pre-existing CVD were excluded, as 
were 58,883 (11.7%) on statins, 3,405 (0.7%) with missing grip data, 2,727 (0.5%) with 
missing self-reported walking pace data, leaving a study population of 406,834.  Table 1 reports 
grip strength range for each sex-specific quintile.  Over a median of 8.87 years of follow-up 
(Q1-Q3 8.25-9.47) there were 7,274 composite fatal/nonfatal events (based on the ACC/AHA 
outcome) and 1,955 fatal events (based on SCORE).   
 
Participants in higher quintiles of grip strength were more likely to be younger and non-
smokers, have lower SBP and higher DBP, and were less likely to be taking antihypertensive 





quintile of mean grip strength had the highest total and HDL cholesterol levels, with those in 
the highest and lowest quintiles showing similar levels. Participants who reported brisk walking 
pace were more likely to be young, white, male, and non-smokers, have lower SBP and DBP, 
and were less likely to report taking antihypertensive medications (Supplemental Table S2). 
The Spearman rank correlation between continuous mean grip and walking pace was +0.138 
(P<.001). 
 
Associations of grip strength and usual walking pace with CVD outcomes 
Higher quintiles of grip strength and faster usual walking pace were associated with lower 
event rates of both CVD outcomes (Table 1). Figure 1 displays the age and sex-specific risk 
matrix for HR of CVD incidence by grip strength and walking pace. The CVD hazard ratio for 
women aged 40-50 years who reported a slow walking pace and who have a low grip strength 
was 2.9, compared to 1.8 and 3.2 for those aged 50-60 and >=60 years, respectively. A similar 
trend was observed for men; however, the HR was lower compared to women – 2.1, 2.0, 2.6 
for men aged 40-50, 50-60 and 60+, respectively. Being a slow walker, regardless of grip 
strength, was associated with a higher risk of CVD in both men and women.     
 
Prediction of CVD events 
For the composite fatal/nonfatal (ACC/AHA) CVD outcome (Figure 2), classical risk factors 
yielded a C-index of 0.7463 (95% CI 0.7406-0.7521). This was improved upon with the 
addition of either grip strength (change in C-index +0.0017, 95% CI 0.0009-0.0026), or self-
reported walking pace (+0.0031, 95% CI 0.0019-0.0043), with the largest improvement seen 
when both were added (+0.0041, 95% CI 0.0027-0.0055). Excluding total and HDL cholesterol 





also improved by the addition of grip strength (+0.0017, 95% CI 0.0008-0.0026), usual walking 
pace (+0.0043, 95% CI 0.0029-0.0056), or both (+0.0052, 95% CI 0.0037-0.0067) (Figure 2).  
 
For the fatal CVD outcome, based on the SCORE CVD risk model (Figure 3), classical risk 
factors yielded a C-index of 0.7707 (95% CI 0.7600-0.7813) which was improved by the 
addition of grip strength (+0.0047, 95% CI 0.002-0.0074), self-reported walking pace 
(+0.0130, 95% CI 0.0088-0.0171), or both (+0.0148, 95% CI 0.0102-0.0194). When the 
SCORE model run without total and HDL cholesterol, the remaining risk factors yielded a C-
index of 0.7700 (95% CI 0.7601-0.7800) which was improved by the addition of grip strength 
(+0.0052, 95% CI 0.0025-0.0078), self-reported walking pace (+0.0156, 95% CI 0.0114-
0.0199) or both (+0.0177, 95% CI 0.0131-0.0224). 
 
For the CVD outcome, we investigated improvement in risk classification across the 7.5% 10 
year risk threshold for statin therapy, used in the AHA/ACC guidelines 19 (Table 2). We found 
that the addition of grip strength resulted in a 0.55% (95% CI 0.12-0.96%) improvement in 
overall reclassification. Similarly, the addition of self-reported walking pace resulted in a 
0.53% (95% CI 0.01-1.06%) improvement in overall reclassification. Adding both grip and 




The main finding of the current study is that, in this large and comprehensive single-protocol 
cohort, the addition of grip strength and/or usual walking place resulted in an improvement in 
the prediction of CVD when added to established CVD risk scores (AHA/ACC and SCORE) 





prediction to a greater extent than grip strength, but the combination of the two provided the 
greatest improvement. These findings clearly suggest that grip strength and usual walking 
place, both of which are cheap, fast and easy to measure, may have utility in clinical practice 
in improving the identification of people at high risk of fatal and non-fatal CVD outcomes who 
would benefit most from primary prevention.  
 
As mentioned previously, several studies have demonstrated that higher grip strength is 
associated with lower risk of a broad range of health outcomes, including CVD 1,2,7–10,12,20–22 
and the current study confirms this association with CVD. Comparatively few studies have 
investigated the association between walking pace and health outcomes, and many of these 
were in older people where they have consistently shown that there is an inverse association 
between objectively measured walking pace and all-cause mortality 1,23. Interestingly, recent 
work has also shown, using data from UK Biobank, that self-reported walking pace is 
associated with a broad range of health outcomes, including CVD 3,24. In fact, usual walking 
pace was, alongside self-reported health, the strongest predictor of death from a range of causes 
in an early analysis of UK Biobank by Ganna and Ingelsson 11. Low walking pace and grip 
strength are also key in the diagnosis of sarcopenia, the age related loss of muscle mass and 
strength, which has been shown to be associated with higher risk of CVD 25,26. 
 
Whilst, to our knowledge, there are no studies which have investigated the addition of walking 
pace to a CVD risk score, our previous work has shown that the addition of grip strength 
resulted in an improvement in risk prediction on top of an office based risk score – which 
included age, sex, diagnosed diabetes, body mass index, systolic blood pressure and smoking 
but did not include lipids 2. The current study has confirmed our previous findings with grip 





office-based risk scores (AHA/ACC and SCORE models minus lipids). Improvements in 
prediction were strongest with the addition of usual walking pace and this is consistent with 
previous work showing usual walking pace is more strongly associated with health outcomes 
than grip strength 11,24. Interestingly, the current data also show that the improvement in risk 
prediction of these office-based scores is additive, with larger improvements in C index when 
both grip strength and usual walking pace were included in the model. Such information has 
clinical utility and highlights that these markers of physical capability may improve risk 
prediction when blood lipid data are not available, as is the case in many rural communities 
and in developing countries.  
 
When lipids were included in the risk score models, similar results were seen. The addition of 
grip strength or usual walking pace improved risk prediction, as demonstrated by the C-index, 
with usual walking pace providing the greatest improvements in the full ACC/AHA and 
SCORE models. When both grip strength and usual walking pace were added to the ACC/AHA 
and SCORE models, the change in C-index was greater than when either were added to the 
models alone suggesting they provide complementary information about risk. The findings 
were corroborated by the change in classification of participants. The  addition of grip strength 
and walking pace individually resulted in 0.55% and 0.53% increases in NRI and when 
combined there was a 1.12% increase in overall net reclassification. These increases in C-index 
and NRI are similar to those seen when adding, for example, troponin I 27 or CRP/fibrinogen 
28 and was indeed of greater magnitude than the addition of, for example, HbA1c 29 or lipid 
related markers 30 to similar risk scores.  These data indicate that the addition of grip strength 
and self-reported usual walking pace can modestly improve CVD risk prediction and as they 
are both cheap and easy to administer they may warrant further consideration for 






Strengths and Limitations 
The current study benefits from a large cohort size with an age that is relevant for CVD risk 
prediction with biochemical assays performed consistent with the internationally recognized 
standard for testing and calibration laboratories (ISO17025). Furthermore, the number of 
events accrued in the current study are considerable in the context of the existing literature. 
However, the study is not without limitations. UK Biobank aimed to be representative of the 
general population in terms of age, sex, ethnicity and socioeconomic status but is 
unrepresentative in terms of lifestyle, with participants less likely to be obese and a lower 
disease frequency – indicative of a “healthy volunteer” selection bias 31. Therefore, caution 
should be heeded in generalizing summary statistics, such as prevalence and incidence, to the 
general population. However, effect sizes should nonetheless be generalizable. We have not 




The addition of both grip strength and usual walking pace to existing risk scores results in 
modest improvements in CVD risk prediction, with an additive effect when both are included. 
As both these measures are cheap, fast and easy to administer these data further indicate that 
these tools could have a useful role in CVD risk screening.  More work in this area would, 
therefore, seem prudent.  
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Figure 1.  CVD Risk matrix for the combine effect of grip strength and walking pace by 
sex and age.  
Risk matrices were developed based on Cox regression models for the overall data, by sex and 
by age and sex groups (40-50, 50-60, 60+ years for both female and male). Self-reported 
walking pace and sex-specific quartiles of handgrip were mutually adjusted in the models, and 
were additional adjusted for age, sex, ethnicity, diabetes, systolic blood pressure, total 
cholesterol, HDL-cholesterol, and smoking. ***P<0.001, **P<0.01, *P<0.05 
 
Figure 2. Change in C-Index for the AHA/ACC composite CVD outcome with the 
addition of grip strength, usual walking pace and both together. 
Data presented as C index and 95% CI and as differences in C index versus classical risk 
factors. Classical risk factors including information on age, sex, ethnicity, systolic blood 
pressure, diastolic blood pressure, antihypertensive medications, smoking and diabetes. 
Handgrip strength was added into the model as quintiles of the continuous average measure 
(categorical), and usual walking pace was a categorical variable.  
 
Figure 3. Change in C-Index for the SCORE fatal CVD outcome with the addition of 
grip strength, usual walking pace and both together 
Data presented as C index and 95% CI and as differences in C index versus classical risk 
factors. Classical risk factors including information on age, sex, ethnicity, systolic blood 
pressure, diastolic blood pressure, antihypertensive medications, smoking and diabetes. 
Handgrip strength was added into the model as quintiles of the continuous average measure 







Table 1. Event rates of both CVD outcomes (composite outcome based on ACC/AHA 
and fatal outcome based on SCORE) among 406,834 UK Biobank participants. 
  Composite CVD (ACC/AHA) Fatal CVD (SCORE) 










Grip strength range in 
italics  
(F: Female,  
M: Male) 
1  
F: 0-18kg  M: 0-32kg 
295.50 282.43-309.16 94.69 87.46-102.53 
2 
F: 18.5-22kg  M: 32.5-37kg 
224.07 213.70-234.96 59.24 54.04-64.96 
3 
F: 22.5-25kg  M: 37.5-41.5kg 
205.04 194.72-215.90 53.83 48.69-59.52 
4 
F: 25.5-28.5kg  M: 42-47kg 
178.57 169.02-188.66 41.74 37.27-46.75 
5  
F: 29-57kg  M: 47.5-85kg 
129.40 121.53-137.78 28.00 24.48-32.04 
Usual walking 
pace 
Slow 428.04 401.14-456.74 169.48 152.98-187.77 
Average 220.35 213.69-227.22 58.97 55.59-62.56 







Table 2. Net Reclassification Index for composite fatal/non-fatal CVD outcomes for 
grip strength, usual walking place and both combined. 
















+Walking pace +0.53% 
(+0.01, +1.06%) 
+0.69% 
(+0.16, +1.22%) 
-0.16% 
(-0.19, -0.13%) 
+Both +1.12% 
(+0.58, +1.69%) 
+1.36% 
(+0.82, +1.93%) 
-0.24% 
(-0.27, -0.21%) 
 
 



